0000000000520310

AUTHOR

Thierry Conroy

showing 2 related works from this author

The EORTC computer-adaptive tests measuring physical functioning and fatigue exhibited high levels of measurement precision and efficiency

2013

Objectives: The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group is developing a computer-adaptive test (CAT) version of the EORTC Quality of Life Questionnaire (QLQ-C30). We evaluated the measurement properties of the CAT versions of physical functioning (PF) and fatigue (FA) and compared these with the corresponding QLQ-C30 scales. Study Design and Setting: Based on international samples of more than 1,000 cancer patients, we simulated CAT administration of varying numbers of items and compared the resulting scores with those based on all items in the respective item pools. Furthermore, the relative validity (RV) of CATs was compared with that of th…

MESH: FatigueMaleEpidemiologyMESH: Aged 80 and over0302 clinical medicinePhysical functioningQuality of lifeNeoplasmsSurveys and QuestionnairesActivities of Daily LivingStatisticsMESH: NeoplasmsDiagnosis Computer-Assisted030212 general & internal medicineFatigueReliability (statistics)MathematicsMESH: AgedAged 80 and overMESH: Middle AgedMiddle Agedhumanities3. Good healthMESH: Reproducibility of ResultsLevel of measurementMESH: Young AdultData Interpretation Statistical030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleAdultmedicine.medical_specialtyAdolescentMean squared errorSensitivity and SpecificityYoung Adult03 medical and health sciencesSDG 3 - Good Health and Well-beingotorhinolaryngologic diseasesmedicineHumansMESH: Surveys and QuestionnairesAgedMESH: AdolescentMESH: HumansMESH: Activities of Daily LivingMESH: Diagnosis Computer-AssistedMESH: Quality of LifeReproducibility of ResultsMESH: Adultsocial sciencesMESH: MaleMESH: Sensitivity and SpecificitySample size determinationQuality of LifePhysical therapy[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieComputerized adaptive testingMESH: Data Interpretation StatisticalMESH: FemaleRelative validity
researchProduct

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

2016

Exclusive chemoradiotherapy (CRT) delivering 50 Gy over 5 weeks with cisplatin and fluorouracil-based chemotherapy is a cornerstone in locally advanced esophageal cancer or non-operable patients since the results of the pivotal study of US Intergroup RTOG-8501 (1). This trial has successfully demonstrated that some patients with esophageal carcinoma may be long-term survivors so that this treatment is now definitely accepted as curative (2). Nevertheless the prognosis is still very disappointing with a 5-year overall survival rate of approximately 25%. Attempts to improve overall survival by escalating the dose of radiotherapy with concurrent cisplatin and fluorouracil has been assessed in …

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtymedicine.medical_treatmentLocally advancedCetuximab[SDV.CAN]Life Sciences [q-bio]/CancerOutcomes[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[ SDV.CAN ] Life Sciences [q-bio]/CancerIntensity-Modulated Radiotherapy03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaMedicineComputingMilieux_MISCELLANEOUSCapecitabineCisplatinChemotherapybusiness.industryCarcinomaInduction ChemotherapyEsophageal cancermedicine.diseaseRadiation-Therapy3. Good healthRadiation therapyEditorial030104 developmental biologyChemoradiationFluorouracil030220 oncology & carcinogenesisIi Randomized-TrialCisplatinbusiness[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractChemoradiotherapymedicine.drug
researchProduct